Capital Allocation
Capital Allocation
Maximus spent the past two years pivoting from paying down the debt it raised for its 2021 VES acquisition to buying back stock — roughly $457 million in fiscal 2025 and about $150 million more into fiscal 2026, at a blended cost near $78 a share [1]. The balance-sheet discipline is real: net leverage never left a 1.5–1.8x band against a stated 2.0–3.0x target [2]. The price discipline is harder to defend — most of those repurchased shares are underwater at $58.
From deleveraging to a buyback
The shape of Maximus's capital allocation is a debt story first. The company entered fiscal 2021 nearly debt-free, then paid roughly $1.36 billion of cash for VES, the veterans-medical-exam business, funding it with about $1.5 billion of new term debt [3]. Buybacks then stopped almost entirely — $3 million in fiscal 2021 and zero in fiscal 2023 — while free cash flow went to debt reduction, taking gross leverage to about 2.2x by September 2023 [4]. Through this stretch management's stated capital-deployment priorities were a growing dividend and acquisitions; repurchases were not on the list [5].
Source: reported cash-flow statements, FY2016–FY2025 10-Ks; the FY2025 figure of $447M is on a settlement (cash) basis, versus the ~$457M executed reported on the earnings call [6]; [7].
By fiscal 2025 the debt was worked down and buybacks resumed sharply. Maximus repurchased about 5.8 million shares for roughly $457 million — more than the prior nine fiscal years of buybacks combined — enabled by two board authorizations that lifted the program to $400 million in September 2025, superseding earlier $200 million resolutions [8] [9]. The buying has continued into fiscal 2026: about 1.4 million shares for $111 million in the March quarter and another 0.6 million for $40 million through May 1, alongside a fresh $400 million authorization effective May 11, 2026 [10].
That activity is the reason earnings-per-share can grow while revenue is flat. Weighted-average diluted shares fell from about 61.5 million in fiscal 2024 to 57.9 million in fiscal 2025, and to 54.6 million in the March 2026 quarter; shares actually outstanding were 53.1 million at March 31, 2026 [11].
Source: reported diluted share counts, FY2020–FY2025 10-Ks and Q2 FY2026 earnings release [12].
The price paid
The count is coming down. What it cost is the less flattering half of the story. Maximus's fiscal-2025 repurchases averaged about $79 a share, and the pace picked up in the September 2025 quarter at an average of $87.64 — near the stock's high before it fell to $58 [13]. Management framed the buying as value-driven: on the May 2026 call it said the "share price does not reflect the intrinsic value of the business" and pointed to "increased capital deployment toward share repurchases, given our view that our shares have been trading at an attractive valuation" [14]. Nine months on, that call has not yet paid off.
Source: FY2025 10-K Item 5 (Q4 average $87.64) [15]; Q4 FY2025 and Q2 FY2026 earnings calls [16] [17]; price per reported daily quotes.
Taken together, Maximus has repurchased roughly 7.8 million shares for about $608 million since October 2024 at a blended cost near $78. At $58.30, that block is worth about $455 million — an unrealized loss on the order of $150 million, or roughly a quarter of the capital deployed. The chart below places the buying against the price it paid: the heaviest purchases landed in the $79–88 zone of late 2025, not the low-$60s the stock reached in 2026.
Source: reported daily closing prices; the concentrated fiscal-2025 buying at ~$88 and the ~$79 March-2026 tranche sit near the top of this range [18].
The counter to a "bought high" reading is that the mark is not the point. The share reduction is permanent regardless of where the stock trades, and Maximus has kept buying as the price fell — from $87.64 in September 2025 to $66.67 by April 2026 — so it is averaging down rather than defending a single price. At today's roughly 15% forward free-cash-flow yield (Cash Conversion), each dollar retired claims more cash per remaining share than a dollar spent at $88 did. What would turn the read negative is a repeat of the fiscal-2025 pattern — the largest buying at the highest prices — rather than the current fall-following behavior.
The discipline that is real
Where management has been consistent is leverage. Its stated priority stack, unchanged across the period, runs organic-growth investment first, then a growing dividend, then disciplined acquisitions, with share repurchases last — all inside a 2.0–3.0x target net-debt ratio [19]. Actual leverage has stayed below that band throughout the buyback: 1.5x at September 2025, rising to 1.8x by March 2026 as short-term borrowing bridged the fiscal-2026 cash-collection gap, still well under the 4.0x credit-agreement covenant ceiling [20] [21]. Management was explicit that repurchases run "within the constraint of our stated target net debt ratio of 2x to 3x" and are sized against near-term liquidity and the acquisition pipeline [22].
That constraint has teeth. Because Maximus's cash arrives late in its fiscal year and leaned on a receivables facility through the fiscal-2026 squeeze (Cash Conversion), buyback capacity is genuinely bounded by liquidity, not just intent — an analyst on the May 2026 call pressed exactly this point [23]. The tension in the record is therefore narrow: management has been disciplined about how much balance sheet to commit and undisciplined, so far, about when to commit it.
The other two legs
The dividend, despite being the higher stated priority, is a token. The quarterly payout moved only from $0.28 in fiscal 2021–2023 to $0.30 for fiscal 2024 and 2025, then to $0.33 declared in April 2026 — about $1.32 annualized, or roughly 15% of guided adjusted earnings [24] [25]. It grows, but slowly enough that it is not where surplus cash goes.
Acquisitions, the third leg, have been quiet since VES. Investing outflows ran $54–129 million a year across fiscal 2022–2025 — capex and small tuck-ins, not another platform deal — even as management keeps saying it is "seeking acquisition targets" [26]. The practical result is that buybacks, officially the lowest priority, have been the swing use of cash: with the dividend fixed low and no deal on the table, repurchases absorbed the free cash flow.
For context, aggressive buyback is the norm in Maximus's own peer group. Science Applications International (SAIC) — one of the six companies Maximus benchmarks against [27] — repurchased about 4.0 million shares for roughly $422 million in its latest year under a $1.2 billion authorization, cutting its diluted count about 7% annually [28]. Maximus's fiscal-2025 step-up brought it into line with a cohort that has long treated buybacks as the primary return of capital; the distinctive feature is the timing, not the scale.
The buyback is the bridge from durable free cash flow to per-share value: management has committed the balance sheet responsibly — leverage below target throughout — but has so far paid prices the market has not validated, leaving the per-share case dependent on the free cash flow holding up rather than on the repurchases being well timed.
Management's own alignment is largely equity-based: the chief executive's fiscal-2025 pay was $11.2 million, roughly $6.9 million of it in stock awards [29]. Insider open-market activity has been limited to small, plan-based director sales, neither a vote of confidence nor a warning.